Kornimate/medical-research-clean huggingface dataset:
cold snare polypectomy vs. cold forceps polypectomy using narrow-band imaging endoscopy for removal of diminutive colorectal polyps

Conditions: Polyp of Large Intestine

Summary: the purpose of this study is to compare cold snare polypectomy and cold forceps polypectomy using narrow-band imaging endoscopy for removal of diminutive colorectal polyps.

previous study found cold snare polypectomy a preferable technique in comparison to cold biopsy for diminutive polyps when assessed for completeness of resection. however, it is expected that cold biopsy polypectomy with advanced endoscopy, such as chromoendoscopy or narrow-band imaging endoscopy, increase completeness of resection. one study showed 90% of the diminutive polyps were completely resected using cold biopsy polypectomy with chromoendoscopy. however, no study compared cold snare polypectomy and cold biopsy polypectomy using narrow-band imaging endoscopy for removal of diminutive colorectal polyps. the aim of this study is to compare cold snare polypectomy and cold biopsy polypectomy using narrow-band imaging endoscopy for removal of diminutive colorectal polyps

Eligibility criteria:
inclusion criteria: * patients over the age of 20 years undergoing routine colonoscopy (screening, surveillance, or diagnostic) exclusion criteria: * patients taking antiplatelet or anticoagulant therapy during the past 1 week of the procedure * known coagulopathy * history of inflammatory bowel diseases * american society of anesthesiology class iii or more * pregnancy.
sexual coercion in breast cancer patients treated with luteinizing hormone-releasing hormone agonists (lhrha )

Conditions: Cancer

Summary: the use of luteinizing hormone-releasing hormone agonists(lhrha) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. however, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being.

objective: the use of luteinizing hormone-releasing hormone agonists(lhrha) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer. however, this approach can lead to more severe and prolonged menopausal symptoms, which can further impact intimate relationships and sexual function. sexual coercion, encompassing both overt and subtle forms of pressure, is a significant global public health concern that threatens individual well-being. methods: this study is a randomized controlled study. in this study, the validated turkish version of the sexual coercion in intimate relationship scale was utilized to investigate whether patients receiving lhrha therapy experienced higher rates of sexual sexual coercion compared to those taking tamoxifen. the study included 40 patients using lhrha and 39 patients using tamoxifen. the instrument assessed partner sexual coercion across three subdomains: resource manipulation/sexual coercion, commitment manipulation, and defection threat.

Eligibility criteria:
inclusion criteria: * being over 18 years of age * willingness to participate in this study * having received treatment for breast cancer * having a history of breast cancer surgery * having an active relationship with a spouse or partner. exclusion criteria: * having any neuropsychiatric disorder * having any mental illness * having a history of gynecological surgery * currently receiving active chemotherapy or less than 3 months since completing chemotherapy * receiving treatment for metastatic disease * the use of selective serotonin reuptake inhibitors

Keywords: breast cancer
a survey to assess participants' and physicians' knowledge, attitudes and behavior when using gattex

Conditions: Short Bowel Syndrome (SBS)

Summary: the main aim of this study is to document the level of knowledge and assess attitudes and behaviors of both participants and physicians regarding the risks and safe use of gattex. the survey will be done via internet, telephone, or paper and both physicians and participants will be able to choose the method that is preferred. no study medicines will be provided to participants in this study.


Eligibility criteria:
participant inclusion criteria: participants who are 18 years of age and who have taken gattex in the 60 days prior to survey implementation are eligible to participate in the survey. a caregiver may participate in this survey on behalf of a patient who is eligible but unable to complete the survey. note: participants who have previously participated in a gattex patient knowledge, attitudes and behavior (kab) survey, are eligible. prescriber inclusion criteria: hcps (adult and pediatric) in the united states who can provide a 10-digit national provider identifier (npi) number and who have prescribed gattex at least once regardless of their completion of the voluntary gattex rems training (prescriber education slide deck) are eligible for participation in the survey. note: hcps who have previously participated in a gattex hcp kab survey, are eligible. participant and prescriber exclusion criteria: * respondents who do not agree to participate in the survey. * respondents who are currently working for and/or whose immediate family members who are currently working for takeda pharmaceuticals u.s.a., inc., nps pharmaceuticals, inc., shire, ubc, or the food and drug administration (fda) are not eligible to participate in the survey. * respondents who reported having a conflict of interest. * hcps who have opted out of receiving communications about the gattex hcp kab survey for the current wave further details associated with respondents who do not meet the exclusion criteria established above, will be provided in the assessment report.
a mri study of visual and motor pathways in premature infants

Conditions: Premature Birth

Summary: approximately 30,000 babies annually are born with extremely low birth weight (elbw) in the us. these babies often have motor and/or visual problems when they grow up. it is very important to identify high risk elbw infants as early as possible, so that the investigators can treat them earlier to prevent poor development. neurological examination at early age is not good enough to identify high risk elbw infants. one the other hand, some magnetic resonance imaging (mri) methods such as diffusion tensor imaging (dti) and resting state functional mri (rfmri) have shown great sensitivity to brain injury which may cause motor and visual problems. therefore, the investigators propose to use dti and rfmri on elbw infants at a very early age to predict long-term outcome and to identify infants who are at high risk of having motor and/or visual problems when they grow up.


Eligibility criteria:
inclusion criteria: * elbw infants with birth weight 401-1000 g (gestational age \<30 weeks) exclusion criteria: * complex congenital anomalies * central nervous system malformations, * chromosomal abnormalities, or hydrops fetalis
silicone gel for postsurgical scars of the eyelid

Conditions: Scarring Due to Treatment

Summary: to determine whether silicone gel is effective at preventing or minimizing scar formation after eyelid surgery.

upper eyelid blepharoplasty or ptosis repair is performed when the upper eyelid becomes droopy, which often occurs as a natural part of the aging process. the droopiness of the upper eyelids decreases the ability to see objects in their peripheral vision, causing functional deficits. additionally, the droopiness can be a cosmetic concern for many. the most effective treatment option is blepharoplasty or ptosis repair. during routine pre-operative counseling, many patients note a fear of prominent facial scarring. different techniques have been described in the literature to minimize scarring, from steroid creams to injections to laser therapy; however, there is currently no consensus for long-term management of post-surgical eyelid scars. specifically, there is no study examining the efficacy of topical silicone gel on eyelid scars, although a few studies have examined its efficacy on other facial scars. silicone is proposed to aid in healing by regulating fibroblast production, reducing collagen production, and modifying expression of growth factors. the investigator's study is designed to determine whether topical silicone may prevent significant post-operative eyelid scar formation. it may help clarify whether there is a safe and effective topical treatment for patients undergoing eyelid surgery for whom scarring or cosmesis is a concern. it is the first study of silicone gel on the eyelid and is also prospective, randomized, and double blinded.

Eligibility criteria:
inclusion criteria: * patients will be included if they have met the criteria for undergoing upper eyelid ptosis repair or blepharoplasty. this means they have droopiness of the upper eyelids that is visually significant and limiting the patient's visual field. exclusion criteria: * patients will be excluded if they require additional upper eyelid surgery.
neurosonographic findings in pregnant women with vitamin d deficiency

Conditions: Neurosonographic Findings of Vitamin D Deficiency

Summary: in the study, the potential effects of vitamin d deficiency on fetal neurodevelopmental parameters will be examined. in this context, fetal brain development will be compared between pregnant women with and without vitamin d deficiency, revealing the possible neurodevelopmental outcomes of vitamin d deficiency during the prenatal period.

vitamin d is a vitamin that regulates calcium and phosphorus balance in the body and plays a crucial role in bone health. additionally, it is known to have effects on immune system functions and neurological health. pregnancy is a period in which vitamin d requirements increase, and vitamin d deficiency can lead to various health problems. it is believed that vitamin d deficiency may have adverse effects on fetal neurological development and may be associated with certain pathological conditions during pregnancy. neurosonography is a critical tool for assessing the effects of prematurity, vitamin d deficiency, and other pregnancy complications on the fetus. this article will focus on the evaluation of neurosonographic findings in pregnant women with vitamin d deficiency.

Eligibility criteria:
inclusion criteria:patients presenting for routine antenatal care between 20-30 weeks of gestation will be included. exclusion criteria:multiple pregnancy, preterm rupture of membranes, chorioamnionitis, placental abruption, severe fetal growth restriction, congenital fetal anomalies, preeclampsia, oligohydramnios and maternal diabetes.

Keywords: neurosonography vitamin d deficiency pregnancy
dosing of overground robotic gait training with functional outcomes and neuroplasticity after spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the door sci project examines dosing effects of robotic gait training (rgt) and transcranial magnetic stimulation (tms) initiated during inpatient rehabilitation and continued through early outpatient rehabilitation

emerging evidence indicates that robotic exoskeleton use results in positive outcomes for those with chronic sci, yet limited evidence exists for the acute setting. the potential benefit of rgt initiated during inpatient rehabilitation when recovery is greatest is unknown yet appears promising due to established principles of neuroplasticity and the fact that rgt incorporates the critical components of gait training. as a result of the lack of evidence, no clinical practice guidelines exist that delineate which gait retraining approach or dose during early phases of recovery results in the best outcomes for people with motor incomplete sci. the door sci project examines dosing effects on 5 occasions over 9 months: (1) inpatient rehabilitation admission and (2) discharge, (3) after completing 24 rgt sessions, (4) 1-month post rgt, and (5) 9-months post sci). to test the overarching goal, investigators propose three specific aims: aim 1: using a randomized controlled trial, prospectively examine whether the dosing frequency \[24 sessions delivered as high, moderate, or low frequency, defined by number days/week (4, 3, or 2 days/week over 6, 8, 12 weeks)\] of rgt therapy provided during the acute/subacute recovery phase after motor incomplete sci impacts outcomes compared to usual care only. aim 2: investigate the difference over 9 months of the neuroplastic effect of rgt dosing as measured by single pulse tms. aim 3: evaluate the safety, tolerability, and feasibility of delivering different dosing frequencies of rgt from inpatient to outpatient rehabilitation settings.

Eligibility criteria:
inclusion criteria: * all types of motor incomplete sci (traumatic and non-traumatic) * acute/subacute phase of recovery * medically stable as deemed by physician * undergoing medical care and rehabilitation at baylor scott \& white institute for rehabilitation * both genders and all races and ethnicities * meet the ekso robotic exoskeleton frame limitations * continence of or a program for bladder and bowel management exclusion criteria: * concurrent moderate to severe traumatic brain injury (tbi) * degenerative diagnoses * pre-morbid developmental disability, significant psychological diagnosis, or other cognitive impairment * pregnancy

Keywords: exoskeleton wearable assistive technology transcranial magnetic stimulation robotic gait training
locomotion and global positioning system in arterial disease

Conditions: Peripheral Arterial Disease

Summary: the maximal walking distance (mwd) performed on treadmill (tt) remains the gold standard in estimating the walking capacity of patients suffering from peripheral arterial disease (pad) with intermittent claudication, although treadmills are not accessible to most physicians. we hypothesized that global positioning system (gps) recordings could monitor community-based outdoor walking and provide valid information on walking capacity in pad patients.

the study has two main objectives, conducted together. each objective include several phases. objective 1: technical validation of gps measurements in healthy subjects. phase 1: technical validation of a gps device to study outdoor walking (completed). phase 2: comparison and use of various gps devices (intra- and inter-gps variability) in the study outdoor walking (on-going). phase 3: study of several factors that could influence accuracy of gps measurements as walking speed, environment, sampling frequency and others technical features as the waas/egnos function (on-going). objective 2: application in pad patients to study walking capacity under free-living conditions phase 1: comparison of gps measurements (maximal walking distance) with the gold standard treadmill measurement of maximal walking distance (completed). phase 2: analysis of the variability of the walking capacity under free-living conditions from gps measurements (completed). phase 3: study of reliability and sensibility (effect of treatment) of gps measurements (on-going). phase 4: study of the relationship between laboratory measurements of walking capacity and gps-derived parameters.

Eligibility criteria:
inclusion criteria: * ankle to brachial index (abi) \< 0.95 for pad patients * age \> 18 years old * able to walk on treadmill exclusion criteria: * limb pain of potential non-vascular origin * myocardial infraction in the last six months * uncontrolled angina pectoris

Keywords: claudication peripheral arterial disease diagnosis exercise walking impairment disability
impact of humeral component version on outcomes following rtsa

Conditions: Rotator Cuff Tear Arthropathy

Summary: the proposed study is a prospective, single-blinded, randomized trial to investigate the impact of humeral component version on shoulder range of motion and patient reported functional outcomes following reverse total shoulder arthroplasty.

retrospective clinical evidence suggests that increasing humeral component retroversion does not affect measured internal or external rotation, however patients with neutral version may experience better function with daily activities requiring internal rotation compared to those with 30 degrees of retroversion. prospective data on clinical outcomes comparing different humeral component versions in rtsa is currently lacking. the proposed study is a prospective, single-blinded, randomized trial to investigate the impact of humeral component version on shoulder range of motion and patient reported functional outcomes following reverse total shoulder arthroplasty.

Eligibility criteria:
inclusion criteria: * patients undergoing primary reverse total shoulder arthroplasty * diagnosis of cuff tear arthropathy or primary oa with rct * intact posterior rotator cuff and subscapularis preoperatively, as determined by surgeon-administered physical exam * 18 years or older exclusion criteria: * revision arthroplasty * diagnosis of rheumatoid arthritis, infection, acute trauma or instability * minors (under 18 years of age) * prior open shoulder surgery * concomitant latissimus dorsi transfer * patients not undergoing a standard of care physical therapy protocol * pregnant, patient-reported * cognitively impaired
study of pet scans and serotonin in hot flashes treatment

Conditions: Hot Flashes

Summary: the purpose of this study is to determine in a preliminary manner whether successful therapy of hot flashes can be associated with changes in the serotonin transporter in the brain. the serotonin transporter is important in delivering serotonin into certain portions of the brains (serotonin is a chemical that is important in the control of body temperature, mood, sleep, and other functions).

hot flashes represent the most common complaint among peri- and postmenopausal women. over 60% of postmenopausal women experience hot flashes, and 10-20% of all postmenopausal women find them nearly intolerable. despite the prevalence of hot flashes, their pathophysiology is not well understood. treatment options include non-pharmacological approaches, hormonal interventions, and non-hormonal pharmacological agents. the most effective treatment for hot flashes is estrogen. the most promising non-hormonal treatments for hot flashes are selective serotonin or noradrenergic reuptake inhibitors (ssri/snri). although estrogen withdrawal is implicated in the initiation of hot flashes, and serotonin's role is well established in thermoregulation, the relationship between estrogen and serotonin is not known. preclinical studies suggest that both estrogen and ssri down regulate the serotonin transporter. clinical studies that further delineate the relationship between effective treatments for hot flashes and the serotonin transporter may shed a new light into the pathophysiology of these symptoms and more importantly, into design of new-targeted treatments.

Eligibility criteria:
inclusion criteria: * postmenopausal women * 7 or more hot flashes per day for at least 3 months * must be able to undergo magnetic resonance (mr) and pet imaging * must be able to receive either paroxetine or estrogen exclusion criteria: * no treatment with hormone therapy or other medications that affect estrogen within the past 3 months * no evidence of a currently active cancer

Keywords: hot flashes, vasomotor symptoms, estrogen, paroxetine
study evaluating erb-041 in active crohn's disease

Conditions: Crohn's Disease

Summary: evaluate the response of inflammatory serum markers to oral erb-041 in subjects with inflammation associated with active crohn's disease.


Eligibility criteria:
inclusion criteria: * men and women, minimum 18 years of age with a diagnosis of crohn's disease greater than 3 months, * eligible subjects must have adequate hematologic, renal, and hepatic function. other inclusions apply exclusion criteria: * use of the following medications within the specified time period before randomization is prohibited: within 48 hours before randomization * nonsteroidal antiinflammatory drugs (nsaids) within 2 weeks before randomization * herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components). other exclusions applies

Keywords: crohn's disease inflammation
a 12-week study treating participants who have alpha1-antitrypsin-related copd with alvelestat (mph966) or placebo.

Conditions: Alpha 1-Antitrypsin Deficiency; Emphysema; COPD

Summary: the purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with pizz, null or rare variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. change in a number of different blood and sputum biomarkers related to lung damage, inflammation and elastase activity will be measured over a 12 week period. the effect on lung function and respiratory symptoms will also be measured.


Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of alpha-1-anti-trypsin deficiency and a pizz, null or other rare geno/phenotype and serum anti-alpha1 antitrypsin levels of less than 11um * fev1 ≥20% predicted * computerised tomography (ct) scan evidence of emphysema * non-smokers exclusion criteria: * primary diagnosis of bronchiectasis * an ongoing acute exacerbation of the underlying lung disease * underlying liver disease or abnormal liver function tests * previous augmentation therapy within 6 months of dosing

Keywords: pizz or null neutrophil elastase inhibitor alpha-1 alvelestat azd9668 mph966 rare variant genotype astraeus aatd alpha 1-antitrypsin deficiency lung disease
an observational study of avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse

Conditions: Glioblastoma Multiforme

Summary: this single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. data will be collected from eligible patients initiated on avastin treatment according to local label for up to 3 years.


Eligibility criteria:
inclusion criteria: * adults patients, \>/= 18 years of age * histologically confirmed glioblastoma multiforme in first or second relapse exclusion criteria: * patients not qualifying for avastin treatment as per local label
guided versus non-guided pelvic floor exercises for urinary incontinence in relapsing-remitting multiple sclerosis

Conditions: Relapsing-Remitting Multiple Sclerosis; Urinary Incontinence

Summary: the aim of the study is to evaluate the effectiveness of guided versus non guided pelvic floor exercises for urinary incontinence in patients with relapsing-remitting multiple sclerosis

subjects of the study should conduct a specific training in pelvic floor exercises. they were randomly assigned into 2 groups: group a only received written instructions for exercises to be performed at home; group b received written instructions and, in addition, exercises were performed in a 30 minutes weekly session with a physiotherapist guiding them

Eligibility criteria:
inclusion criteria: 1. diagnosed with relapsing-remitting multiple sclerosis 2. diagnosed with urinary incontinence 3. minimental sate examination (mmse) scale: more than 24 4. expanded disability status scale (edss) scale: bladder function 0-4; edss 0-6,5 5. willing to participate in the study 6. having signed an informed consent exclusion criteria: 1. diagnosed with another neurological disease 2. diagnosed with kidney diseases 3. having a relapse of the disease in the last 6 months 4. in women: pregnancy os postpartum \< 6 months 5. having gone through surgery for urinary incontinence or prolapses or prostate diseases 6. having gone through other treatment for pelvic floor 7. mmse scale: under 24 8. edss scale: bladder function 5-6 or not knowing; edss 7-10 9. iciq-sf scale: severity 19-21 10. not willing to participate or sign the informed consent form or not able to understand the study

Keywords: pelvic floor muscle exercise supervision physiotherapy